Countries
Industry
Startup stage
Startup size
Funding
Impact startup SDGs
Showing: 10750 filtered startups

Shortcut AS

Shortcut is a leading mobile innovation company. Spread cross Oslo, Bergen and Copenhagen. We are a collection of 80 + Developers, Designers, Architects and Project Managers. Together with our customers, we have succeeded in building digital tools used by millions every day. Our company culture is characterised by idealism, integrity, curiosity, and togetherness, fortified by a playful sense of humour and our love of technology. We employ people from all over the world who deliver outstanding technical and design solutions across all platforms, developing applications for iOS, Android, Cloud + Windows.

UBIQ Aerospace

UBIQ Aerospace was founded in late 2017, with the mission of providing enabling technologies to unmanned and autonomous aircraft. We aspire to hire great people that immerse themselves into key issues and obstacles experienced in the industry and through dedicated processes, with stakeholders, to design and develop solutions that bring great value to our customers and the industry. The first tech. is the proprietary D•ICE technology, an autonomous icing protection solution for unmanned aircraft. The D•ICE tech is the only autonomous icing protection solution available. With its dedicated icing detection algorithms and intelligent control algorithms, D•ICE requires no third-party sensors and no human-interaction.

Factlines AS

Factlines' digital solution and expertise make supply chain mapping efficient by supporting the entire process, from requirements and code of conduct to risk analysis, follow-up, and dialogue. Our mission and vision: We are dedicated to helping businesses manage CSR compliance in their supply chains. Our web-based solutions, and execution services, ease the burden for our customers and turn their efforts into value. We unite supply chains into a meaningful symbiotic collaboration, empowering both a better world and increased profit. CSR Reporting: Secure and time-saving solution for meeting the Socially Responsible Public Procurement (SRPP) criteria for non-financial reporting. Supply Chain Management: Follow each supplier and sub-supplier individually at as many levels as you want. Maintain information on every actor in the chain and share it securely. Contract Management: Manage the risks, and keep track of all the compulsory documentation, statistics, contracts' expiration dates, and other qualification documents. Contact us: info@factlines.com

OKTO

OKTO is a gamification of outdoor cycling. OKTO gives you the fun of friendly competition, you compete with riders on your own level - both locally and all over the world. By completing quests, journeys, and achievements you gain OKTO points, fun rewards, titles, and more to help you reach the next level.

Infraspace AS

Infraspace is a new cloud-based platform for early-stage infrastructure planning and design. Save time. Lower costs. Reduce environmental impact. We focus on the early stage planning and design of the projects. That's when changes have the biggest impact on costs, quality, and sustainability. Infraspace is a new platform to empower teams to make better decisions based on data and analyses. ✅Optimization algorithms ✅Cost and CO2 estimates ✅Environmental analyses

Apotek 1

Apotek 1 er Norges største apotekkjede og vi er i stadig vekst. Hos oss jobber ca. 3500 dedikerte medarbeidere, og vi er også landets største farmasøytiske arbeidsgiver. Vi har en stolt kultur med klare ambisjoner om alltid å leve opp til vårt slagord 'Vår kunnskap - din trygghet' i våre kundemøter. Kompetanse og kvalitet er kjernen for vår virksomhet, og derfor er faglig og personlig videreutvikling av våre medarbeidere helt sentralt i kjeden. I Apotek 1 er vi opptatt av å etterleve våre verdier som er: pålitelig, frisk, engasjert og nær. Vi bestreber at dette skal prege alle ansatte, alle beslutninger, alle handlinger og alle mål i selskapet. Apotek 1 Gruppen AS er eiet av den tyske Phoenix-gruppen. Servicekontor og distribusjonsenhet ligger på Lørenskog i Akershus. Vi er landets største leverandør av legemidler pakket i multidose, samt legemidler og tjenester til kommunehelsetjenesten, blant annet legemiddelgjennomganger.

Knitting Inna AS

Vi søker etter en aktiv partner med kompetanse og kapital til å ta nettbutikken vår til neste nivå. «Vi» er mor og sønn fra Ålesund som de siste årene har gjort det veldig bra innen design av strikk til hele familien. Vi har gitt ut 4 bestselgende strikkebøker med et samlet opplag på 100.000, og skal straks i gang med bok nummer 5. I tillegg selger vi garnet vi bruker til våre design i nettbutikken. Firmaet vårt heter Knitting Inna As og brandet vårt heter Bystrikk.   Nettbutikken er lokalisert i Oslo, og vi har en veletablert plattform og kundemasse, og gjør det bra i sosiale medier med 50k følgere på Insta og 26k følgere på Facebook. Vi søker en investor som kan bidra til å øke veksten i vår nettbutikk betraktelig. Nordmenn handler garn for nesten 1,5 milliard kroner i året. Vi startet forsiktig for 3 år siden og har bygget opp selskapet stein for stein, uten kapital eller lån. Vi omsatte for knappe 3,5 millioner i 2019. Nå er vi klare for å utvide virksomheten og ta en langt større del av kaken (1,5 mrd). Med de rette kreftene på laget burde man lett kunne 10-doble omsetningen innen 1-2 år. Vi søker noen som kan stille med både kapital til å utvide virksomhet / varelager, samt strategisk rådgivning innen netthandel og markedsføring. Der bør også komme til noen flere hoder og hender, slik at vi kan få «arbeidsro» til å jobbe videre med utvikling, ekspansjon og salg / markedsføring. Vi har et stort navn og et innarbeidet brand i bransjen og burde ha alle forutsetninger for å lykkes, men pr i dag er vi kun 1,5 årsverk som driver alt og vi har pr i dag ikke nok timer i døgnet, eller kapital, til å ta nettbutikken videre til neste nivå.   Vil du være med på strikkeeventyret vårt?

Nordic Brain Tech

Migraine is an underdiagnosed and undertreated brain disease. 1 in 7 people worldwide is affected by migraine. Nordic Brain Tech develops a treatment that is home-based and self-administered. The invention has gotten worldwide attention from key opinion leaders within migraine. There is a huge market need, and a willingness to pay for the product from both hospitals and migraine patients.

Med-Storm GO

Med-Storm's Skin Conductance Algesimeter (SCA) uses the principle of skin conductance to measure pain, allowing us to titrate the right amount of pain medication for each, individual patient. This award-winning technology is not affected by changes in blood circulation, heart rate, hypotensia, environmental temperatures, and hypoxia, and shows low variation between individuals at the same level of pain. The pain monitor can be used on patients as young as 23 weeks of gestational age, as well as geriatric patients. MS is currently working on a miniaturized and wireless version of the SCA.

Nutcracker Solutions AS

Nutcracker Solutions owns the product StadiaPitch by Bosch Rexroth and have licensed it to Bosch Rexroth until 2038.  The product is sold worldwide by the Bosch Corporation, and Nutcracker is a part of Bosch`s International StadiaPItch sales team. The goal is to reach 4 sales a year. Bosch pays Nutcracker a license fee between €1M - €1.5M per sale. 90% of the fee is due 5 months after Bosch has signed the contract with the stadium. Nutcracker has a flat predictable annual operating cost of €0.4M, regardless of how many StadiaPitch Sales Bosch Rexroth has in that year.  StadiaPitch entered the commercial phase in 2018 and has received an overwhelming market response. StadiaPitch is today included in the architectural drawings on three stadium projects, and Bosch has solid interest from several of the largest clubs in the world. StadiaPitch has received interest from architects, stadiums, and other stakeholders from 25 countries in the last 12 months.  Nutcracker is a dividend stock and the company is priced at 40 MNOK – pre-money. Nutcracker runs a Private Placement of 1OMNOK through a share issue that will equal to 20% of the new total number of shares. This funding will be spent on IPR, activities that enhance Bosch`s global sales work, and operating costs until we get income from the first Bosch contract. We pay a preference dividend equivalent to 50% of the investment for new investors. We have a commitment of 9 MNOK and we close the placement when we reach after the NXT 2019 events.

CoreAll AS

CoreAll is developing game-changing core drilling technology for the E&P industry. The Intelligent Coring System includes real-time coring process control with true formation evaluation data and the ability to core and drill with the same bottom hole assembly. The system has been patented in multiple countries. The development of the main system has successfully been completed with support from Lundin Norway, Spirit Energy, DEA, The Research Council of Norway and Innovation Norway. The system has completed four successful field tests in test wells and is ready for commercial introduction. CoreAll is seeking investors to finance the commercial operations capability. CoreAll was one of only two SME winners of the prestigious Spotlight on Technology award at the OTC in Houston in May 2018.

Folkeinvest AS

GI ALLE MULIGHET TIL Å INVESTERE I VEKSTSELSKAPER GJENNOM AKSJEKJØP. Folkeinvest AS ønsker med webtjenesten folkeinvest.no å demokratisere investering i oppstartsselskaper.Emisjonsprosessen har frem til nå være komplisert både for selskapet og de som vil investere. Derfor har slike investeringer vanligvis kun blitt tilbudt bekjente av selskapet og profesjonelle investorer.Folkefinansiering med lave minstebeløp og en lettfattelig webtjeneste gir alle mulighet til å investere.Å investere i oppstartsselskaper er forbundet med risiko for at investeringen kan gå tapt. Mange selskaper overlever ikke sine fem første år. Men det er også i den fasen at verdistigningen kan bli høy. Vi mener at denne investeringsmuligheten bør være tilgjengelig for alle.Folkeinvest.no har åpne investorlister, diskusjonsforum og krav til dokumentasjon som gjør at aksjekjøpere er godt rustet til å ta investeringsbesluttninger.

VITALOOP AS

At Vitaloop, we are working on giving you clean water everywhere. We make it whole again, removing substances and pollution left by our actions. In a rapidly changing world, Vitaloop will be insurance, proven access to the one thing no one can exist without – clean, fresh, and healthy water. Our go-to-market product is called VITALOOP ORIGIN and is a ground-breaking, patented, high-tech water cleaning bottle that can remove almost everything harmful, manufactured and caused by climate change. It's your own mobile water filtration station using the revolutionary nanomaterial Graphene. It runs by a powerful pump and a rechargeable battery that will clean 450 ml of water in 60 seconds. Vitaloop Origin provides true independence wherever and whenever. VITALOOP- Water restored.

Seald AS

Bile duct cancer is an aggressive form of cancer with an extremely poor overall five-year survival rate of just 2-5 %. Classified as an orphan disease, annual incidence in Europe and the United States of 15-22,000 patients, and a significantly higher incidence in Asia, makes it a major player and the deadliest of the gastrointestinal cancers. Only a small number of patients are eligible for a complete surgical resection by local resection or liver transplantation, and more than 50% of these relapse. The vast majority are treated by gemcitabine-based palliative chemotherapy with a life expectancy of 11 months, and five-year survival rate of zero %. Thus, there is an urgent and unmet medical need to develop new and better treatment strategies for these patients. The innovations developed by Seald are a result of adopting a multidisciplinary approach to the diagnosis and treatment of bile duct cancer, based on extensive drug sensitivity assays on living cancer cells, molecular biomarkers, DNA sequencing, extensive bioinformatics analyses and zebrafish models. Sealds’s holistic approach is unique with possible modes of action that can be used on other solid cancers. Our technology includes drug repurposing and innovation on new medical substances, diagnostics and methodology. The stipulated pharma market globally is USD 2.1-4.2 billion, in addition to the markets for diagnostics and platform technology

Qtime AS

Hvorfor velge oss? Tradisjonell varehandel står ovenfor store utfordringer i konkurranse med veksten i netthandel. Spesielt presserende er utfordringer i forhold til kjøpsopplevelse, effektivitet og lønnsomhet. ​ Vårt fokus i Qtime er å hjelpe varehandelen til å løse nettopp disse utfordringene. Gi kundene dine den beste handleopplevelsen, med fremtidens kundestrømsverktøy.